{"doi":"10.1177/030089169408000105","title":"Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer","abstract":"<jats:sec>\n                    <jats:title>Aims and background</jats:title>\n                    <jats:p>Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue that induces the suppression of gonadal steroidogenesis, and it could therefore be a medical alternative to irreversible surgical castration. We report the clinical and endocrine results from 40 goserelin-treated premenopausal patients with advanced breast cancer.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>A depot formulation of the drug (3.6 mg s.c.) was administered fortnightly for the first 4 doses, and monthly thereafter. Gonadotrophins and estradiol (E2) levels were measured before and at specific times during the treatment.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>Objective responses were observed in 17 of the 38 evaluable patients (45%), six of whom achieved complete remission. The best responses were observed on soft tissues (65%). Castration E2 levels were achieved in all of the patients.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Our results confirm that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer.</jats:p>\n                  </jats:sec>","journal":"Tumori Journal","year":1994,"id":650955,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1697561,"name":"Luigi Celio","orcid":null,"position":1,"is_corresponding":false},{"id":1697562,"name":"Nicoletta Zilembo","orcid":null,"position":2,"is_corresponding":false},{"id":1697563,"name":"Aldo Bono","orcid":null,"position":3,"is_corresponding":false},{"id":1697564,"name":"Domenico Galluzzo","orcid":null,"position":4,"is_corresponding":false},{"id":1194059,"name":"Maria Giulia Zampino","orcid":"0000-0001-5142-1778","position":5,"is_corresponding":false},{"id":1697567,"name":"Alessandra Longhi","orcid":null,"position":6,"is_corresponding":false},{"id":1697568,"name":"Leonardo Ferrari","orcid":null,"position":7,"is_corresponding":false},{"id":760351,"name":"Roberto Buzzoni","orcid":null,"position":8,"is_corresponding":false},{"id":1537473,"name":"Emilio Bajetta","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer","abstract":"<jats:sec>\n                    <jats:title>Aims and background</jats:title>\n                    <jats:p>Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue that induces the suppression of gonadal steroidogenesis, and it could therefore be a medical alternative to irreversible surgical castration. We report the clinical and endocrine results from 40 goserelin-treated premenopausal patients with advanced breast cancer.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>A depot formulation of the drug (3.6 mg s.c.) was administered fortnightly for the first 4 doses, and monthly thereafter. Gonadotrophins and estradiol (E2) levels were measured before and at specific times during the treatment.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>Objective responses were observed in 17 of the 38 evaluable patients (45%), six of whom achieved complete remission. The best responses were observed on soft tissues (65%). Castration E2 levels were achieved in all of the patients.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Our results confirm that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":2.639057329615259,"endowment":2.639057329615259,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"8191594","pmcid":null,"openalex_id":"https://openalex.org/W2413332153","authors":[],"funders":[],"total_grants":0,"fwci":0.4546,"citation_percentile":0.68521996,"influential_citations":0,"citation_trend":[{"year":2014,"count":1}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.1177/030089169408000105","host_type":"publisher"},{"url":"https://doi.org/10.1177/030089169408000105","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/8191594","host_type":"repository"}],"fields_of_study":["Estrogen and related hormone effects","Hypothalamic control of reproductive hormones","Breast Cancer Treatment Studies","Adult","Breast Neoplasms","Delayed-Action Preparations","Estrogens","Female","Gonadotropins, Pituitary","Goserelin","Humans","Middle Aged","Ovary","Premenopause","Progesterone","Survival Analysis","Treatment Outcome"],"mesh_terms":["Adult","Breast Neoplasms","Delayed-Action Preparations","Estrogens","Female","Gonadotropins, Pituitary","Humans","Middle Aged","Ovary","Progesterone","Survival Analysis","Treatment Outcome","Goserelin","Premenopause"],"keywords":["Goserelin","Medicine","Castration","Oophorectomy","Breast cancer","Internal medicine","Hormone","Endocrine system","Triptorelin","Cancer","Endocrinology","Oncology","Gonadotropin-releasing hormone","Luteinizing hormone","Hysterectomy","Surgery"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T06:23:56.740720Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}